The activation of an effective anti-tumor immune response requires cancer antigens to be taken up and processed by antigen-presenting cells (APCs) which in turn present antigen-derived peptides to CD8+ and CD4+ T cells in complex with HLA class I and II molecules, respectively [14]. This evidence concerns the gene CD8A and neoplasm.